Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

Cited by (1,041)

Items 701–800 of 1,041

1. Defective Repair of Oxidative DNA Damage in Triple-negative Breast Cancer Confers Sensitivity to Inhibition of Poly(ADP-ribose) Polymerase
   Elizabeth Alli, Vandana B. Sharma, Preethi Sunderesakumar, J. Ford · 2009 · Cancer Research
2. Cellular and molecular consequences of defective Fanconi anemia proteins in replication-coupled DNA repair: Mechanistic insights
   Larry H. Thompson, John M. Hinz · 2009 · Mutation research. Fundamental and molecular mechanisms of mutagenesis
3. Evolutionary Pathways in BRCA1-Associated Breast Tumors
   Filipe Correia Martins, Subhajyoti De, Vanessa Almendro, Mithat Gönen, So Yeon Park, Joanne L. Blum, William G. Herlihy, Gabrielle Ethington, Stuart J. Schnitt, Nadine Tung et al. · 2012 · Cancer Discovery
4. Pharmacological Targeting of Cell Cycle, Apoptotic and Cell Adhesion Signaling Pathways Implicated in Chemoresistance of Cancer Cells
   Dauren S. Alimbetov, Sholpan Askarova, Bauyrzhan A. Umbayev, Terence Davis, David Kipling · 2018 · International Journal of Molecular Sciences
5. Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}- N -methylpyridine-2-carboxamide (AZD5305): A PARP1–DNA Trapper with High Selectivity for PARP1 over PARP2 and Other PARPs
   Jeffrey W. Johannes, Amber Balazs, Derek G. Barratt, Michał Biśta, Matthew D. Chuba, Sabina C. Cosulich, Susan E. Critchlow, Sébastien L. Degorce, Paolo Di Fruscia, Scott D. Edmondson et al. · 2021 · Journal of Medicinal Chemistry
6. Genomic instability in breast cancer: Pathogenesis and clinical implications
   Kevin A. Kwei, Yvonne Kung, Keyan Salari, Ilona N. Holcomb, Jonathan R. Pollack · 2010 · Molecular Oncology
7. PARPs and the DNA damage response
   Fabrício Garmus Sousa, Renata Matuo, Daniele Grazziotin Soares, Alexandre E. Escargueil, João Antônio Pêgas Henriques, Annette Kragh Larsen, Jenifer Saffi · 2012 · Carcinogenesis
8. Poly(ADP-Ribose) Polymerase Inhibition: “Targeted” Therapy for Triple-Negative Breast Cancer
   Carey K. Anders, Eric P. Winer, James M. Ford, Rebecca Alexandra Dent, Daniel P. Silver, George W. Sledge, LA Carey · 2010 · Clinical Cancer Research
9. mTORC1 pathway in DNA damage response.
   Yin-Xing Ma, Y. Vassetzky, Svetlana Dokudovskaya · 2018 · Biochimica et biophysica acta. Molecular cell research
10. PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers
    Man Keung, Yanyuan Wu, Jaydutt V. Vadgama · 2019 · Journal of Clinical Medicine
11. The RNA Splicing Response to DNA Damage
    Lulzim Shkreta, Benoı̂t Chabot · 2015 · Biomolecules
12. Hereditary ovarian cancer: Beyond the usual suspects
    Kathryn P. Pennington, Elizabeth M. Swisher · 2012 · Gynecologic Oncology
13. Biomarkers in triple negative breast cancer: A review
    Budhi Singh Yadav · 2015 · World Journal of Clinical Oncology
14. Drugging the addict: non‐oncogene addiction as a target for cancer therapy
    Remco Nagel, Ekaterina A Semenova, Anton J. M. Berns · 2016 · EMBO Reports
15. Potential drugs used in the antibody–drug conjugate (ADC) architecture for cancer therapy
    Sajad Yaghoubi, Mohammad Hossein Karimi, Majid Lotfinia, Tohid Gharibi, Motahare Mahi‐Birjand, Esmaeil Kavi, Fahimeh Hosseini, Koushan Sineh Sepehr, Mehrdad Khatami, Nader Bagheri et al. · 2019 · Journal of Cellular Physiology
16. DEAD Box 1 Facilitates Removal of RNA and Homologous Recombination at DNA Double-Strand Breaks
    Lei Li, Devon R. Germain, Ho-Yin Poon, Matthew R. Hildebrandt, Elizabeth A. Monckton, Darin McDonald, Michael J. Hendzel, Roseline Godbout · 2016 · Molecular and Cellular Biology
17. How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies
    Ji Hyun Park, Jin Hee Ahn, Sung‐Bae Kim · 2018 · ESMO Open
18. Suppression of HIV-1 infection by a small molecule inhibitor of the ATM kinase
    Alan Lau, Karra M. Swinbank, Parvin S. Ahmed, Debra L. Taylor, Stephen P. Jackson, Graeme C.M. Smith, Mark J. O’Connor · 2005 · Nature Cell Biology
19. Advances in using PARP inhibitors to treat cancer
    Shivaani Kummar, Alice P. Chen, Ralph E. Parchment, Robert J. Kinders, Jay Ji, Joseph E. Tomaszewski, James H. Doroshow · 2012 · BMC Medicine
20. Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization
    Stéphanie Lheureux, Zhongwu Lai, Brian Andrew Dougherty, Sarah K. Runswick, Darren Hodgson, Kirsten M. Timms, Jerry S. S. Lanchbury, Stan B. Kaye, Charlie Gourley, David D.L. Bowtell et al. · 2017 · Clinical Cancer Research
21. PARP-3 Is a Mono-ADP-ribosylase That Activates PARP-1 in the Absence of DNA
    Olga Loseva, Ann‐Sofie Jemth, Helen E. Bryant, Herwig Schuler, L. Lehtiö, T. Karlberg, Thomas Helleday · 2010 · Journal of Biological Chemistry
22. Poly(ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis
    Lucio Tentori, Pedro Miguel Lacal, Alessia Muzi, Annalisa Susanna Dorio, Carlo Leonetti, Marco Scarsella, Federica Ruffini, Weizheng Xu, Wokee Min, Antonella Stoppacciaro et al. · 2007 · European Journal of Cancer
23. Clinicopathological Features of Homologous Recombination–Deficient Epithelial Ovarian Cancers: Sensitivity to PARP Inhibitors, Platinum, and Survival
    Asima Mukhopadhyay, Elizabeth Ruth Plummer, Ahmed Elattar, San Soohoo, Bisha Fathamah Uzir, Jennifer E. Quinn, Wilson Glenn McCluggage, Perry Maxwell, Harriet Aneke, Nicola J. Curtin et al. · 2012 · Cancer Research
24. MRE11 Deficiency Increases Sensitivity to Poly(ADP-ribose) Polymerase Inhibition in Microsatellite Unstable Colorectal Cancers
    Eduardo Vilar, Catherine M. Bartnik, Stephanie L. Stenzel, Leon Raskin, Jaeil Ahn, Victor Rau Moreno, Bhramar Mukherjee, Maria D. Iniesta, Meredith Ann Morgan, Gad Rennert et al. · 2011 · Cancer Research
25. Defective ALC1 nucleosome remodeling confers PARPi sensitization and synthetic lethality with HRD
    Graeme Hewitt, Valérie Borel, Sandra Segura‐Bayona, Tohru Takaki, Phil Ruis, Roberto Bellelli, Laura C. Lehmann, Lucia Sommerová, Aleksandra Vančevska, Antonia Tomás‐Loba et al. · 2020 · Molecular Cell
26. Targeted therapy for breast cancer: An overview of drug classes and outcomes
    Aaron T. Jacobs, Diana Martinez Castaneda-Cruz, Mark M. Rose, Linda Connelly · 2022 · Biochemical Pharmacology
27. Testicular cancer: Determinants of cisplatin sensitivity and novel therapeutic opportunities
    Gerda de Vries, Ximena Rosas-Plaza, Marcel A.T.M. van Vugt, Jourik A. Gietema, Steven de Jong · 2020 · Cancer Treatment Reviews
28. A new wave of innovations within the DNA damage response
    Qi Li, Wenyuan Qian, Yang Zhang, Lihong Hu, Shuhui Chen, Yuanfeng Xia · 2023 · Signal Transduction and Targeted Therapy
29. Familial Pancreatic Cancer
    Kieran A. Brune, Alison P. Klein · 2008 · Springer eBooks
30. Overcoming implementation challenges of personalized cancer therapy
    Funda Meric‐Bernstam, Gordon Brent Mills · 2012 · Nature Reviews Clinical Oncology
31. Biallelic Deleterious BRCA1 Mutations in a Woman with Early-Onset Ovarian Cancer
    Susan M. Domchek, Jiang-bo Tang, Jill E. Stopfer, Dana R. Lilli, Nancy Hamel, Marc D. Tischkowitz, Álvaro N.A. Monteiro, Troy E. Messick, Jacquelyn Powers, Alexandria Yonker et al. · 2012 · Cancer Discovery
32. Ubiquitylation, neddylation and the DNA damage response
    Jessica S. Brown, Stephen P. Jackson · 2015 · Open Biology
33. Recent advancement of piperidine moiety in treatment of cancer- A review
    Pallavi Goel, Ozair Alam, Mohd. Javed Naim, Farah Nawaz, Muzaffar Iqbal, Iqbal Alam · 2018 · European Journal of Medicinal Chemistry
34. DNA Replication Vulnerabilities Render Ovarian Cancer Cells Sensitive to Poly(ADP-Ribose) Glycohydrolase Inhibitors
    Nisha Pillay, Anthony Tighe, Louisa Nelson, Samantha Littler, Camilla Coulson‐Gilmer, Nourdine Kabirou Bah, Anya Golder, Björn Bakker, Diana C.J. Spierings, Dominic I. James et al. · 2019 · Cancer Cell
35. First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial
    Karim S. Fizazi, Arun Azad, Nobuaki Matsubara, Joan Carles, André P. Fay, Ugo De Giorgi, Jae Young Joung, Peter C.C. Fong, Éric Voog, Robert J. Jones et al. · 2023 · Nature Medicine
36. Mass spectrometry for the assessment of the occurrence and biological consequences of DNA adducts
    Shuo Liu, Yinsheng Wang · 2015 · Chemical Society Reviews
37. PARP inhibitors: the race is on
    Jessica S. Brown, Stan B. Kaye, Timothy Anthony Yap · 2016 · British Journal of Cancer
38. Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer Therapy
    Gianluca Papeo, Helena Posteri, Daniela Borghi, Alina A. Busel, Francesco Caprera, Elena Casale, Marina Ciomei, Alessandra Cirla, Emiliana Corti, Matteo D’Anello et al. · 2015 · Journal of Medicinal Chemistry
39. Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile
    Kimberly L. Cramer-Morales, Margaret Nieborowska-Skorska, Kara A. Scheibner, Michelle R. Padget, David A. Irvine, Tomasz Śliwiński, Kimberly Haas, Jae Woong Lee, Huimin Geng, Darshan B. Roy et al. · 2013 · Blood
40. AGO Recommendations for Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2013
    Nadia Harbeck, Anton J. Scharl, Christoph Thomssen, Volkmar Müller · 2013 · Breast Care
41. Biomarkers of Response and Resistance to DNA Repair Targeted Therapies
    Elizabeth H. Stover, Panagiotis A. Konstantinopoulos, Ursula A. Matulonis, Elizabeth M. Swisher · 2016 · Clinical Cancer Research
42. A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67
    Bojana Jovanović, Ingrid A. Mayer, Erica L. Mayer, Vandana Gupta Abramson, Aditya Bardia, Melinda E. Sanders, Maria Gabriela Kuba, Monica Valeria Estrada, J. Scott Beeler, Timothy M. Shaver et al. · 2017 · Clinical Cancer Research
43. Targeted cancer therapies based on the inhibition of DNA strand break repair
    Mark J. O’Connor, Niall M.B. Martin, Graeme C.M. Smith · 2007 · Oncogene
44. PARPs and ADP-ribosylation in RNA biology: from RNA expression and processing to protein translation and proteostasis
    Dae-Seok Kim, Sridevi Challa, Aarin Jones, W. Lee Kraus · 2020 · Genes & Development
45. PARP inhibitors in ovarian cancer: Current status and future promise
    Joyce F. Liu, Panagiotis A. Konstantinopoulos, Ursula A. Matulonis · 2014 · Gynecologic Oncology
46. Chromatin and the DNA damage response: The cancer connection
    Martijn S. Luijsterburg, Haico van Attikum · 2011 · Molecular Oncology
47. Parthanatos and its associated components: Promising therapeutic targets for cancer
    Yunxiang Zhou, Lihong Liu, Sifeng Tao, Yihan Yao, Yali Wang, Qichun Wei, Anwen Shao, Yongchuan Deng · 2020 · Pharmacological Research
48. ALC1 links chromatin accessibility to PARP inhibitor response in homologous recombination-deficient cells
    Priyanka Verma, Yeqiao Zhou, Zhendong Cao, Peter V. Deraska, Moniher Deb, Eri Arai, Weihua Li, Yue Shao, Laura N. Puentes, Yiwen Helen Li et al. · 2021 · Nature Cell Biology
49. Aurora kinase A, a synthetic lethal target for precision cancer medicine
    Pui Kei Mou, Eun Ju Yang, Changxiang Shi, Guowen Ren, Shishi Tao, Joong Sup Shim · 2021 · Experimental & Molecular Medicine
50. Prospects for combining immune checkpoint blockade with PARP inhibition
    Li, Anping, Yi, Ming, Qin, Shuang, Chu, Qian, Luo, Suxia, Wu, Kongming · 2019 · Journal of Hematology & Oncology
51. Potentiation of Peptide Receptor Radionuclide Therapy by the PARP Inhibitor Olaparib
    Julie Nonnekens, Melissa van Kranenburg, Cecile E. M. T. Beerens, Mustafa Suker, Michail Doukas, Casper H.J. van Eijck, Marion de Jong, Dik C. van Gent · 2016 · Theranostics
52. Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways
    Todd W. Miller, Sarah R. Hosford · 2014 · Pharmacogenomics and Personalized Medicine
53. ATR Pathway Inhibition Is Synthetically Lethal in Cancer Cells with ERCC1 Deficiency
    Kareem N. Mohni, Gina M. Kavanaugh, David Cortez · 2014 · Cancer Research
54. Functional Viability Profiles of Breast Cancer
    Rachel Brough, Jessica R. Frankum, David Sims, Alan G. Mackay, Ana M. Mendes‐Pereira, Ilirjana Bajrami, Sara Costa-Cabral, Rumana Rafiq, Amar Sabri Ahmad, Maria Antonietta Cerone et al. · 2011 · Cancer Discovery
55. A mouse model of basal‐like breast carcinoma with metaplastic elements
    Afshan McCarthy, Kay Savage, Anastasia Gabriel, Cristina Naceur‐Lombardelli, JS Reis‐Filho, Alan Ashworth · 2007 · The Journal of Pathology
56. Triple-negative breast cancer
    Rupert Bartsch, Reinhard Ziebermayr, Christoph Carl Zielinski, Guenther G. Steger · 2010 · Wiener Medizinische Wochenschrift
57. Mammalian Rif1 contributes to replication stress survival and homology-directed repair
    Sara B.C. Buonomo, Yipin Wu, David O. Ferguson, Titia de Lange · 2009 · The Journal of Cell Biology
58. Tumor Mutation Burden Forecasts Outcome in Ovarian Cancer with BRCA1 or BRCA2 Mutations
    Nicolai J. Birkbak, Bose S. Kochupurakkal, José M. G. Izarzugaza, Aron Charles Eklund, Yang Li, Joyce F. Liu, Zoltán Szállási, Ursula A. Matulonis, Andrea L. Richardson, James Dirk Iglehart et al. · 2013 · PLoS ONE
59. Right on target: eradicating leukemic stem cells
    Daniela S. Krause, Richard A. Van Etten · 2007 · Trends in Molecular Medicine
60. RAD51C-Deficient Cancer Cells Are Highly Sensitive to the PARP Inhibitor Olaparib
    Ahrum Min, Seock‐Ah Im, Young‐Kwang Yoon, Sang‐Hyun Song, Hyun-Jin Nam, Hyung-Seok Hur, Hwang‐Phill Kim, Kyung-Hun Lee, Sae‐Won Han, Do‐Youn Oh et al. · 2013 · Molecular Cancer Therapeutics
61. Triple negative breast cancer: shedding light onto the role of pi3k/akt/mtor pathway
    Daniela Massihnia, Antonio Galvano, Daniele Fanale, Alessandro Perez, Marta Castiglia, Lorena Incorvaia, Angela Listì, Sérgio Rizzo, Giuseppe Cicero, Viviana Bazan et al. · 2016 · Oncotarget
62. Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond
    Stergios Boussios, Charlotte Abson, Michele Moschetta, Elie Rassy, Afroditi Karathanasi, Tahir Bhat, Faisal Iftikhar Ahmed Ghumman, Matin Sheriff, Nicholas A. Pavlidis · 2020 · Drugs in R&D
63. Glioblastoma Multiforme
    Kevin Anton, Joachim M. Baehring, Tina M. Mayer · 2012 · Hematology/Oncology Clinics of North America
64. Deconstructing the molecular portrait of basal-like breast cancer
    Fruma Yehiely, José V. Moyano, Joseph R. Evans, Torsten O. Nielsen, Vincent L. Cryns · 2006 · Trends in Molecular Medicine
65. BRCAness, Homologous Recombination Deficiencies, and Synthetic Lethality
    Junko Murai, Yves G. Pommier · 2023 · Cancer Research
66. A High-Throughput Functional Complementation Assay for Classification of <i>BRCA1</i> Missense Variants
    Bouwman, Peter, van der Gulden, Hanneke, van der Heijden, Ingrid, Drost, Rinske, Klijn, Christiaan N., Prasetyanti, Pramudita, Pieterse, Mark, Wientjens, Ellen, Seibler, Jost, Hogervorst, Frans B.L. et al. · 2013 · Cancer Discovery
67. Harnessing the complexity of DNA-damage response pathways to improve cancer treatment outcomes
    Fares Al‐Ejeh, R Kumar, Adrian P. Wiegmans, Sunil R. Lakhani, Michael Paul Brown, Kum Kum Khanna · 2010 · Oncogene
68. BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1
    Rinske Drost, Kiranjit K. Dhillon, Hanneke M.L. van der Gulden, Ingrid van der Heijden, Inger Brandsma, Cristina Cruz, Dafni Chondronasiou, Marta Castroviejo‐Bermejo, Ute Boon, Eva Schut et al. · 2016 · Journal of Clinical Investigation
69. Using sulfuramidimidoyl fluorides that undergo sulfur(vi) fluoride exchange for inverse drug discovery
    Gabriel J. Brighty, Rachel C. Botham, Suhua Li, Luke T. Nelson, D.E. Mortenson, Gencheng Li, Christophe H.P. Morisseau, Hua Wang, Bruce D. Hammock, Karl Barry Sharpless et al. · 2020 · Nature Chemistry
70. Context-Dependent Glioblastoma–Macrophage/Microglia Symbiosis and Associated Mechanisms
    Wenjing Xuan, Maciej S. Lesniak, Charles David James, Amy B. Heimberger, Peiwen Chen · 2021 · Trends in Immunology
71. Targeting the nucleotide salvage factor DNPH1 sensitizes BRCA -deficient cells to PARP inhibitors
    Kasper Fugger, Ilirjana Bajrami, Mariana Silva dos Santos, Sarah Jane Young, Simone Kunzelmann, Geoff P. Kelly, Graeme Hewitt, Harshil Patel, Robert J. Goldstone, Thomas Carell et al. · 2021 · Science
72. Targeted Therapy for Breast Cancer
    Ali Mohamed, Kenneth Krajewski, Burcu Çakar, Cynthia X. Ma · 2013 · American Journal Of Pathology
73. Efficacy of Chemotherapy in BRCA1/2 Mutation Carrier Ovarian Cancer in the Setting of PARP Inhibitor Resistance: A Multi-Institutional Study
    Joo Ern Ang, Charlie Gourley, C. Bethan Powell, Hilda A. High, Ronnie Shapira‐Frommer, Vincent Castonguay, Jacques De Grève, Tina Atkinson, Timothy Anthony Yap, Shahneen Kaur Sandhu et al. · 2013 · Clinical Cancer Research
74. Targeting DNA damage repair in small cell lung cancer and the biomarker landscape
    Triparna Sen, Carl Michael Gay, Lauren A. Byers · 2018 · Translational Lung Cancer Research
75. Medicinal chemistry approaches of poly ADP-Ribose polymerase 1 (PARP1) inhibitors as anticancer agents - A recent update
    Priyancy G. Jain, Bhumika Patel · 2019 · European Journal of Medicinal Chemistry
76. Noncanonical views of homology-directed DNA repair
    Priyanka Verma, Roger A. Greenberg · 2016 · Genes & Development
77. The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer
    Jiyoung Rhee, Sae‐Won Han, Do‐Youn Oh, Jee Hyun Kim, Seock‐Ah Im, Wonshik Han, In Ae Park, Dong‐Young Noh, Yung‐Jue Bang, Tae‐You Kim · 2008 · BMC Cancer
78. Role of Autophagy in Breast Cancer
    Vassiliki Karantza, Eileen White · 2007 · Autophagy
79. Synthetic viability by BRCA2 and PARP1/ARTD1 deficiencies
    Xia Ding, Arnab Ray Chaudhuri, Elsa Callén, Yan Pang, Kajal Biswas, Kimberly D. Klarmann, Betty K. Martin, Sandra Sczerba Burkett, Linda Cleveland, Stacey Stauffer et al. · 2016 · Nature Communications
80. Precision oncology in the age of integrative genomics
    Chandan Kumar‐Sinha, Arul M. Chinnaiyan · 2018 · Nature Biotechnology
81. Genetic screens in isogenic mammalian cell lines without single cell cloning
    Peter C. DeWeirdt, Annabel K. Sangree, Ruth E. Hanna, Kendall R Sanson, Mudra Hegde, Christine Strand, Nicole S. Persky, John G. Doench · 2020 · Nature Communications
82. Rapid Detection and Signaling of DNA Damage by PARP-1
    Nootan Pandey, Ben E. Black · 2021 · Trends in Biochemical Sciences
83. Inhibition of Poly(ADP-Ribose) Polymerase Modulates Tumor-Related Gene Expression, Including Hypoxia-Inducible Factor-1 Activation, during Skin Carcinogenesis
    David Martín‐Oliva, Rocío Aguilar‐Quesada, Francisco O’Valle, José Antonio Muñoz‐Gámez, Rubén Martínez‐Romero, Raimundo García del Moral, José Mariano Ruiz de Almodóvar, Raquel Villuendas, Miguel Angel Piris, Francisco Javier Oliver · 2006 · Cancer Research
84. Poly-(ADP-ribose)-polymerase inhibitors as radiosensitizers: a systematic review of pre-clinical and clinical human studies
    Paul Lesueur, François Chevalier, Jean-Baptiste Austry, Waïsse Waïssi, Hélène Burckel, Georges Noël, Jean‐Louis Habrand, Yannick Saintigny, Florence Joly · 2017 · Oncotarget
85. Small-Molecule Inhibitors Targeting DNA Repair and DNA Repair Deficiency in Research and Cancer Therapy
    Sarah R Hengel, Maria Spies, Maria Spies · 2017 · Cell chemical biology
86. Telomere Length and Oxidative Stress and Its Relation with Metabolic Syndrome Components in the Aging
    Graciela Gavia-García, Juana Rosado-Pérez, Taide Laurita Arista-Ugalde, Itzen Aguíñiga-Sánchez, Edelmiro Santiago‐Osorio, Vı́ctor Manuel Mendoza-Núñez · 2021 · Biology
87. PARP1 inhibitors trigger innate immunity via PARP1 trapping-induced DNA damage response
    Kim, Chiho, Wang, Xu-Dong, Yu, Yonghao · 2020 · eLife
88. Poly(ADP-Ribose) Polymerase Inhibition as a Model for Synthetic Lethality in Developing Radiation Oncology Targets
    Anthony J. Chalmers, Mina Lakshman, Norman Hok Ling Chan, Robert Glen Bristow · 2010 · Seminars in Radiation Oncology
89. A novel poly(ADP-ribose) polymerase inhibitor, ABT-888, radiosensitizes malignant human cell lines under hypoxia
    Stanley K. Liu, Carla L. Coackley, Mechthild Krause, Farid Jalali, Norman Hok Ling Chan, Robert Glen Bristow · 2008 · Radiotherapy and Oncology
90. ABT-888 Confers Broad In vivo Activity in Combination with Temozolomide in Diverse Tumors
    Joann P. Palma, Yichun Wang, Luis Eduardo Rodriguez, Debra Montgomery, Paul A. Ellis, Gail T. Bukofzer, Amanda L. Niquette, Xuesong Liu, Yan Shi, Loren M. Lasko et al. · 2009 · Clinical Cancer Research
91. Mutational Signatures in Breast Cancer: The Problem at the DNA Level
    Serena Nik‐Zainal, Sandro Morganella · 2017 · Clinical Cancer Research
92. Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibition
    Brittany M. Haynes, Junko Murai, Jung‐Min Lee · 2018 · Cancer Treatment Reviews
93. Inhibiting Wee1 and ATR kinases produces tumor-selective synthetic lethality and suppresses metastasis
    Amirali B. Bukhari, Cody Wayne Lewis, Joanna J. Pearce, Deandra Luong, Gordon K. T. Chan, Armin M. Gamper · 2019 · Journal of Clinical Investigation
94. Genetic interactions of G-quadruplexes in humans
    Katherine G. Zyner, Darcie S Mulhearn, Santosh Adhikari, Sergio Martínez Cuesta, Marco Di Antonio, Nicolas Erard, Gregory J. Hannon, David Tannahill, Shankar Balasubramanian · 2019 · eLife
95. Mechanism and current progress of Poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancer
    Feiyue Zheng, Yi Zhang, Shuang Chen, Xiang Weng, Yuefeng Rao, Fang Hongmei · 2020 · Biomedicine & Pharmacotherapy
96. Ubiquitinated-PCNA protects replication forks from DNA2-mediated degradation by regulating Okazaki fragment maturation and chromatin assembly
    Tanay Thakar, Wendy Leung, Claudia M. Nicolae, Kristen E. Clements, Binghui Shen, Anja‐Katrin Bielinsky, George‐Lucian Moldovan · 2020 · Nature Communications
97. Leveraging the replication stress response to optimize cancer therapy
    Emily Cybulla, Alessandro Vindigni · 2022 · Nature reviews. Cancer
98. Current Treatment Landscape for Early Triple-Negative Breast Cancer (TNBC)
    Jieun Lee · 2023 · Journal of Clinical Medicine
99. Redox Regulation of DNA Repair: Implications for Human Health and Cancer Therapeutic Development
    Meihua Luo, Hongzhen He, Mark R. Kelley, Millie M. Georgiadis · 2009 · Antioxidants and Redox Signaling
100. BRCA1 and BRCA2: Chemosensitivity, Treatment Outcomes and Prognosis
     William David Foulkes · 2006 · Familial Cancer